Pierfranco Conté
0000-0002-5210-5344
Publication & Citation Trends
Publications
1,239 total
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.
Cited by 8
Semantic Scholar
Abstract P4-02-30: Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer
Cited by 0
Semantic Scholar
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial OA
Cited by 7
Semantic Scholar
Abstract PD13-11: PD13-11 Final Overall Survival Analysis of Monarch 2 : A Phase 3 trial of Abemaciclib Plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Cited by 12
Semantic Scholar
The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis OA
Cited by 2
Semantic Scholar
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
Cited by 31
Semantic Scholar
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy OA
Cited by 5
Semantic Scholar
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
Cited by 59
Semantic Scholar
Research Topics
Cancer Treatment and Pharmacology
(304)
Breast Cancer Treatment Studies
(268)
HER2/EGFR in Cancer Research
(264)
Advanced Breast Cancer Therapies
(256)
Lung Cancer Treatments and Mutations
(130)
Affiliations
Semmelweis University
Université Paris-Sud
University of Pisa
University of North Carolina at Chapel Hill
Roche (Switzerland)